Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Exelixis, Inc.
Reckitt Benckiser is expecting its OTC sales to be hit by a weak cold and flu season this year, as the social distancing measures introduced to quash the COVID-19 outbreak also disrupt the circulation of seasonal illnesses.
$600m settlement with DOJ over Suboxone marketing includes corporate integrity agreement and exclusion of subsidiary from government health programs. Indivior also agrees to pay $10m to FTC and be enjoined from future antitrust violations.
Pataday Once Daily Relief Extra Strength is the same formulation as Novartis' Rx Pazeo. It will be the first OTC eye drop indicated for allergy itch with 24-hour efficacy, available online in September and through retailers in early 2021.
Reckitt hires P&G veteran to lead its transformation, while Italy's Angelini and Switzerland's Weleda have new country chiefs.
- Other Names / Subsidiaries
- X-Ceptor Therapeutics, Inc.